Article: Nanobac Life Sciences, Inc. Announces International Journal of Pathophysiology Publication Demonstrating Reversal of Coronary Artery Calcification.

Nanobac Life Sciences, Inc. (OTCPK: NNBP), announced today the publication of a study titled "Calcification in Coronary Artery Disease Can Be Reversed by EDTA - Tetracycline Long-Term Chemotherapy" in the peer reviewed International Journal of Pathophysiology (DOI 10.1016/J.Pathophys.2004.06.001, http://www.sciencedirect.com/). The observational study, conducted by Benedict Maniscalco, M.D., F.A.C.C. of St. Joseph's Hospital, Tampa Florida, demonstrated a statistically significant reversal in the coronary artery calcium (CAC) scores of patients with stable coronary artery disease (CAD) taking Nanobac's proprietary comET nanobiotic regimen. CAC is the deposition of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!